Mehmet Hamdi ÖRÜM

Investigation of the relationship between cannabis use, opioid use and cognitive errors

Cognitive errors associated with cannabis and opioid have been investigated and compared, but the relationship between cognitive errors questioning personal achievements (PA) and interpersonal relationships (IP) with these two types of substance has not been adequately investigated. We aimed to compare comorbid psychiatric symptoms, cognitive errors and substance use characteristics of patients diagnosed with cannabis use disorder (CUD) and opioid use disorder (OUD). In this cross-sectional study, Symptom Checklist-90-Revised (SCL-90-R) was used and a sociodemographic data was obtained. The cognitive distortions scale (CDS) was used to evaluate cognitive errors. The patient group consisted of 60 (30 CUD and 30 OUD) and the control group consisted of 30 males. Patient and control groups were similar in terms of mean age and educational status (p>0.05). The mean duration of substance use of the CUD group was 43.56±31.13 months, while the OUD group was 68.00±33.20 months (p=0.005). The somatic (SOM) (p=0.011) and paranoid (PAR) (p=0.005) subscales of SCL-90-R were significantly different in the CUD and OUD groups. There was a significant difference between CUD and OUD groups in terms of IP (p=0.002) and PA (p=0.002) sub scores and total scores (p = 0.001) of CDS. Our study reveals that cannabis use is associated with more cognitive errors than opioid use. Higher scores of SOM and PAR in the OUD group than in the CUD group were thought to be associated with longer substance use.

PDF

___

1. Dregan A, Gulliford MC. Is illicit drug use harmful to cognitive functioning in the midadult years? A cohort-based investigation. Am J Epidemiol. 2012;175(3):218-27.

2. Örüm MH, Kara MZ, Kuştepe A, et al. Bilişsel hatalar ve dikkat-eksikliği hiperaktivite bozukluğu belirtilerinin madde kullanım özellikleri ile ilişkisi. Bağımlılık Dergisi–Journal of Dependence. 2019;20(2):47-60.

3. Orum MH, Kustepe A, Kara MZ, et al. Addiction profiles of patients with substance dependency living in Adiyaman province. Medicine Science. 2018;7(2):369-72.

4. Kaya-Bozkurt E, Çelik M, Kalenderoğlu A, et al. Autistic symptoms in children with attention deficit hyperactivity disorder. The Journal of Neurobehavioral Sciences. 2019;6(1):6-11.

5. Ozen ME, Orum MH, Kalenderoglu A, et al. Attention-deficit/hyperactivity disorder in patients attending remedial treatment due to substance use disorder in Adiyaman University Training and Research Hospital. Psychiatry and Behavioral Sciences. 2018;8(2):57-62.

6. Kustepe A, Kalenderoglu A, Celik M, et al. Evaluation of impulsivity and complex attention functions of subjects with substance use: Sample from Adiyaman province. Medicine Science. 2019;8(1):67-71.

7. Wang K, Xu M, Ji Y, et al. Altered social cognition and connectivity of default mode networks in the co-occurrence of autistic spectrum disorder and attention deficit hyperactivity disorder. Aust N Z J Psychiatry. 2019:4867419836031.

8. Özdel K, Taymur I, Guriz SO, et al. Measuring cognitive errors using the cognitive distortions scale (CDS): Psychometric properties in clinical and non-clinical samples. PLoS ONE. 2014;9:e105956.

9. American Psychiatric Association. Diagnostic and statistical manual of mental disorders 5th edition. Washington, DC: Author. 2013.

10. Kılıç M. Belirti Tarama Listesi (SCL-90-R)’nin geçerlilik ve güvenirliği. Psikolojik Danışma ve Rehberlik Dergisi. 1991;1:45-52.

11. Doğan S, Öncü B, Varol-Saraçoğlu G, ve ark. Erişkin Dikkat Eksikliği Hiperaktivite Bozukluğu Kendi Bildirim Ölçeği (ASRS-v1.1): Türkçe formunun geçerlilik ve güvenilirliği. Anadolu Psikiyatri Dergisi. 2009;10:77- 87.

12. Covin R, Dozois DJA, Ogniewicz A, et al. Measuring cognitive errors: Initial development of the Cognitive Distortions Scale (CDS). Int J Cogn Ther. 2011;4:297-322.

13. Ögel K. Madde kullanım bozuklukları epidemiyolojisi. Turkiye Klinikleri J Int Med Sci. 2005;1:61-64.

14. Egilmez OB, Örüm MH, Dumlupınar E, et al. Denetimli serbestlik uygulaması kapsamında yapılan başvuruların geriye dönük olarak değerlendirilmesi: 2018 yılı verileri. Bağımlılık Dergisi – Journal of Dependence. 2019;20:80-7.

15. Orum MH, Kara MZ, Egilmez OB, et al. Evaluation of probation implementations of drug users in Adiyaman university training and research hospital: A one-year retrospective study. Medicine Science. 2018;7:754-8.

16. Evren EC, Ögel K, Çakmak D. Esrar ve meperidin (Petidin) kullanım bozukluğu nedeni ile yatarak tedavi gören hastaların özeliklerinin karşılaştırılması. Anadolu Psikiyatri Dergisi. 2002;3:20-27.

17. Altuner D, Engin N, Gürer C, et al. Madde kullanımı ve suç ilişkisi: kesitsel bir araştırma. Tıp Araştırmaları Dergisi. 2009;7:87-94.

18. Ögel K, Tamar D, Evren C, et al. Madde kullanıcılarının özellikleri: Gözden geçirme. Psikiyatri Psikoloji Psikofarmakoloji (3P) Dergisi. 1999;7:5-32.

19. Welsh JW, Knight JR, Hou SS, et al. Association between substance use diagnoses and psychiatric disorders in an adolescent and young adult clinicbased population. J Adolesc Health. 2017;60:648-52.

20. Herken H, Bodur S, Kara F. Üniversite öğrencisi kızlarda madde kullanımı ile kişilik ve ruhsal belirti ilişkisi. Klinik Psikiyatri. 2000;3:40-5.

21. De Crescenzo F, Cortese S, Adamo N, et al. Pharmacological and nonpharmacological treatment of adults with ADHD: a meta-review. Evid Based Ment Health. 2017;20:4-11.

22. Egilmez OB, Örüm MH, Kara MZ. Adıyaman ili AMATEM verilerinin geriye dönük olarak incelenmesi: 2018 yılı verileri. Bağımlılık Dergisi-Journal of Dependence. 2019;20:88-96.

23. Ozturk Y, Akay A. Attention deficit hyperactivity disorder and substance use disorders. Turkiye Klinikleri Child Psychiatry-Special Topics. 2015;1:64-7.

24. Benich JJ 3rd. Opioid dependence. Prim Care. 2011;38:59-70.

25. Kosten TR, O’Connor PG. Management of drug and alcohol withdrawal. New Engl J Med. 2003;348:1786-95.

26. Trull TJ, Waudby CJ, Sher KJ. Alcohol, tobacco, and drug use disorders and personality disorder symptoms. Exp Clin Psychopharmacol. 2004;12:65-75.

27. Curran HV, Freeman TP, Mokrysz C, et al. Keep off the grass? Cannabis, cognition and addiction. Nat Rev Neurosci. 2016;17:293-306.

28. Özen ME, Örüm MH, Kalenderoğlu A. Hot shower therapy in cannabinoid hyperemesis syndrome: A case report. FNG & Bilim Tıp Dergisi. 2018;4:142- 4.

29. Volkow ND, Swanson JM, Evins AE, et al. Effects of cannabis use on human behaviour, including cognition, motivation, and psychosis: A review. JAMA Psychiatry. 2016;73:292-7.

30. Saban A, Flisher A, Laubscher R, et al. The association between psychopathology and substance use: adolescent and young adultsubstance users in inpatient treatment in Cape Town, South Africa. Pan Afr Med J. 2014;17:8.